ArticleResearch in pharmaceutical sciences2025
Expression and functional characterization of an anti-CD22 scFv targeting B-cell malignancies.
Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a recombinant biosimilar single-chain variable fragment antibody targeting human estrogen receptor α36.Research in pharmaceutical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Single-chain variable fragments (scFvs) offer advantages over full-length monoclonal antibodies in cancer therapy, including reduced size, lower production costs, and easier handling. However, Experimental approach: The CD22-scFv construct was subcloned into pET-28a(+) and expressed in Findings/Results: CD22-scFv was successfully expressed in Rosetta (DE3) but not Rosetta-gami 2. Hybrid purification yielded 15.86 mg/L protein, outperforming native purification (3.65 mg/L). Flow cytometry confirmed the binding of native- and hybrid-purified CD22-scFv to CD22 Raji cells with 75.5% and 55.8% efficiency, respectively. Native-purified CD22-scFv significantly inhibited Raji cell proliferation while sparing CD22 Conclusion and implications: This study established a scalable and cost-effective strategy for producing functional CD22-scFv with high specificity and anti-proliferative effects. The findings highlight its potential for targeted therapies and diagnostics, warranting further
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.